| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA789: Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations |
|
Medicine details |
|
| Medicine name | tepotinib (Tepmetko®) |
| Formulation | 225 mg film-coated tablet |
| Reference number | 4146 |
| Indication | Treatment of advanced non-small cell lung cancer (NSCLC) with mesenchymal–epithelial transition (MET) exon 14 skipping mutations or MET amplification |
| Company | Merck KGaA |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 14/04/2022 |
| NICE guidance | TA789: Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations |
| Commercial arrangement | PAS |